IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 241 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.32 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $149 | +161.4% | 12,948 | +86.0% | 0.00% | 0.0% |
| Q4 2023 | $57 | +39.0% | 6,961 | -23.1% | 0.00% | +50.0% |
| Q3 2023 | $41 | -36.9% | 9,052 | -1.5% | 0.00% | -33.3% |
| Q2 2023 | $65 | +16.1% | 9,194 | -0.6% | 0.00% | +50.0% |
| Q1 2023 | $56 | -5.1% | 9,247 | -0.4% | 0.00% | -33.3% |
| Q4 2022 | $59 | -99.9% | 9,280 | -16.9% | 0.00% | -25.0% |
| Q3 2022 | $107,000 | -31.4% | 11,164 | -20.8% | 0.00% | -20.0% |
| Q2 2022 | $156,000 | -33.3% | 14,088 | +0.2% | 0.01% | -16.7% |
| Q1 2022 | $234,000 | -24.0% | 14,065 | -12.9% | 0.01% | 0.0% |
| Q4 2021 | $308,000 | -22.2% | 16,147 | +0.5% | 0.01% | -33.3% |
| Q3 2021 | $396,000 | -9.2% | 16,069 | -4.1% | 0.01% | +12.5% |
| Q2 2021 | $436,000 | -25.2% | 16,759 | +33.3% | 0.01% | -33.3% |
| Q4 2020 | $583,000 | +181.6% | 12,574 | +100.1% | 0.01% | +140.0% |
| Q3 2020 | $207,000 | – | 6,283 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 3,019,201 | $26,720,000 | 20.38% |
| Broadfin Capital, LLC | 5,951,153 | $52,668,000 | 6.92% |
| GREAT POINT PARTNERS LLC | 5,567,348 | $49,271,000 | 6.23% |
| Avoro Capital Advisors LLC | 10,261,039 | $90,810,000 | 5.43% |
| FRAZIER MANAGEMENT LLC | 2,188,331 | $19,367,000 | 5.00% |
| Prosight Management, LP | 1,062,500 | $9,403,000 | 4.85% |
| Perceptive Advisors | 12,241,111 | $108,333,000 | 4.12% |
| Ghost Tree Capital, LLC | 1,000,000 | $8,850,000 | 3.21% |
| QVT Financial LP | 1,021,361 | $8,696,000 | 2.84% |
| Vivo Capital, LLC | 1,600,000 | $14,160,000 | 1.81% |